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Abstract
Cell differentiation is remarkably stable but can be reversed by somatic cell nuclear transfer, cell fusion, and iPS. Nuclear
transfer to amphibian oocytes provides a special opportunity to test transcriptional reprogramming without cell division.
We show here that, after nuclear transfer to amphibian oocytes, mitotic chromatin is reprogrammed up to 100 times faster
than interphase nuclei. We find that, as cells traverse mitosis, their genes pass through a temporary phase of unusually high
responsiveness to oocyte reprogramming factors (mitotic advantage). Mitotic advantage is not explained by nuclear
penetration, DNA modifications, histone acetylation, phosphorylation, methylation, nor by salt soluble chromosomal
proteins. Our results suggest that histone H2A deubiquitination may account, at least in part, for the acquisition of mitotic
advantage. They support the general principle that a temporary access of cytoplasmic factors to genes during mitosis may
facilitate somatic cell nuclear reprogramming and the acquisition of new cell fates in normal development.
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Introduction
Normal development, as well as nearly all cases of experimen-
tally induced changes in gene transcription, is accompanied by cell
division. It is therefore hard to distinguish those molecular events
which prepare cells for, or engage them in, mitosis from those that
are required specifically for transcriptional reprogramming. The
relationship between the cell cycle and cell fate decisions has for a
long time attracted interest [1]. Transition through mitosis is a
time when many transcription factors are displaced from
chromatin, potentially permitting new transcription factors to
occupy chromatin sites on mitotic exit and so direct a postmitotic
cell fate change [2–5]. Mitotic remodelling has been shown to be
of great importance for the efficient replication of erythrocyte
nuclei by Xenopus egg extracts [6,7]. For new transcription, cell
division seems to be needed in some cases [8,9] but not in others
[10,11]. Here we have used nuclear transfer to amphibian oocytes
to compare directly the ability of mitotic chromatin or interphase
nuclei to be reprogrammed in the absence of cell division.
Germinal vesicle (GV) stage oocytes do not replicate or divide.
They therefore provide an opportunity to test whether the cell
cycle phase of donor nuclei affects the efficiency of nuclear
reprogramming as judged by active transcription of previously
silenced genes [12]. To our surprise, we found that a mitotic state
of donor nuclei dramatically increases the efficiency of activating
certain quiescent pluripotency genes in these nuclei. Our results
support an idea that a brief period during mitosis facilitates an
exchange of gene regulatory factors on chromatin and that this
could be an important mechanism to help cells embarking on new
cell lineages during normal development.
Results
Mitotic Chromatin Is Reprogrammed Much More Rapidly
Than Interphase Nuclei
Permeabilized mouse C2C12 cells, a cultured myoblast cell line
which we have used extensively in our oocyte nuclear transfer
experiments, were arrested at specific stages of the cell cycle
(Figure S1a) and were injected into the GV of oocytes (Figure 1a).
The DNA content of these donor cell populations (Figure 1b)
confirmed cell cycle arrest in each of the cell cycle stages. The
transcriptional reactivation of three silent genes quiescent in
C2C12 cells (Nanog, Oct4, and Sox2) was assessed by RT-qPCR
38 h after nuclear transplantation (Figure 1c). Nuclei at a late
stage of the cell cycle (M) show greatly enhanced transcription of
each of the genes when compared to unsynchronized nuclei
(predominantly G1 and S), whereas an already active gene (c-jun)
shows little increase in transcript level. Particularly impressive is
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the 100-fold enhancement in Sox 2 expression from mitotic donor
nuclei when compared to interphase donor nuclei (Figure 1c). In
over 50 experiments, donor cells arrested in mitosis or in late G2
always generated more Sox2 transcripts from reactivated genes at
25–48 h after injection to oocytes than unsynchronized donor
cells. This difference ranged from a few fold to over 100-fold and is
much affected by the exact duration of nocodazole treatment.
Sox2 is a gene that is more widely expressed than most others,
notably in early embryos, in most stem cells, and in the nervous
system [13].
To test whether this result is a peculiarity of this donor cell
type (C2C12 myoblasts) or is a nonspecific effect of nocodazole,
we repeated these experiments with 10T1/2 donor nuclei
(Figure S1b) or prepared mitotic C2C12 donor cells without any
inhibitors by a shake-off procedure (Figure S1c). In both cases,
enhanced transcription from mitotic donors was observed,
although the magnitude of mitotic advantage was lower
(particularly in the case of the shake-off samples, many cells of
which appeared to be apoptotic by visual inspection). Mitotic
donor nuclei were also prepared using another cell synchroni-
zation agent (Taxol), and the mitotic advantage was again seen
(Figure S1d). When G1/G0 cells were exposed to nocodazole
for the same period of time as used to prepare mitotic cells, no
enhancement of transcription of the genes was observed (Figure
S1e). These results indicate that the observed mitotic advantage
is not due to a nonspecific activity of nocodazole nor to a
peculiarity of one line of cells (C2C12).
To ask if this mitotic advantage applies more widely in the
genome than to the pluripotency genes so far tested, we compared
by RNAseq the genes transcribed in injected oocytes by interphase
nuclei or mitotic chromatin. We focussed our analysis on genes
that were found to be consistently expressed by interphase nuclei
after nuclear transfer. One experiment indicated that 617 genes
were transcribed in oocytes at least 2-fold more in mitotic nuclei
compared to interphase nuclei. Of these mitotically up-regulated
genes, Sox2 was 4-fold more transcribed than in interphase
nuclear transfers, and over half of the 617 genes were more
strongly transcribed than Sox2. The list of these genes is in Table
S1.
Mitotic Advantage Is Due to an Increased Rate of
Reprogramming
The enhanced reprogramming from mitotic donor material
could be due to an increased rate or to a greater eventual level of
reprogramming. To distinguish these ideas and to measure the
rate of reprogramming, we measured the incorporation of GFP-
tagged histone B4 (an early marker of oocyte reprogramming) [14]
and the association of Cherry-labelled histone H2B by live
imaging of mixed populations of mitotic and interphase donor cells
after injection into oocytes (see Figure S2a for design). Mitotic
donor material becomes very rapidly marked with both histone B4
and histone H2B, whereas interphase donor nuclei show a lag in
the association of both and particularly of H2B (Figure 2a). In
support of a difference in the rate of reprogramming, we find that
oocyte-derived TBP2 marks the transplanted mitotic cells more
strongly than interphase donor cells (Figure S2b; compare white
mitotic with yellow interphase arrows). We then asked if there is a
more rapid association and activation of RNA polymerase II with
mitotic chromatin. We used immunostaining for the elongating
form of RNA polymerase II on a mixed population of mitotic and
interphase nuclei injected into oocyte GVs. Mitotic donor material
is clearly marked with elongating Pol II before interphase donor
material (Figure 2b, compare panels ii and iv for pol II). In view of
this difference between the two nuclear types in the onset of global
pol II transcription after nuclear transfer, we asked whether
reprogrammed genes are activated at a different rate in mitotic
donor cells compared to interphase cells or if the magnitude of
activation is greater. A time course of reprogramming from
oocytes injected with either interphase or mitotic donor cells was
assessed by RT-qPCR and revealed that genes from mitotic donor
cells are activated more rapidly than the same genes from
interphase cells (Figure 2c); the accumulation of transcripts
reached by 63 h is similar.
We conclude that the difference in reprogramming between
interphase and mitotic donor material giving this mitotic
advantage reflects the rate of reprogramming rather than the
eventual magnitude of transcript generation from these two types
of nucleus.
Mitotic Advantage Is Independent of Nuclear Membrane
Permeability
The most obvious explanation for this mitotic advantage is the
absence of a nuclear envelope in the mitotic karyoplasts. We have
quantitated this difference in membrane permeability by time
course imaging a mixture of injected interphase nuclei and mitotic
karyoplasts. We carried out a ‘‘double permeabilization,’’ in which
both the cell and nuclear membranes, of interphase or mitotic
donor cells, were permeabilized as illustrated in the scheme in
Figure 3a. We then compared the rate of oocyte factor uptake
with the rate of reprogramming by RT-qPCR. A difference in the
amount of B4 and H2B uptake is indeed seen after plasma
permeabilization with digitonin (Figure 3b) but is no longer seen
after double permeabilization of the nuclear envelope with Triton
(Figure 3c). Nevertheless, the mitotic difference between inter-
phase and mitotic chromatin does persist in respect of the
transcriptional reprogramming of silenced genes (Figure 3d).
We have confirmed this conclusion using permeabilization by
different reagents. Streptolysin 0 (SLO) permeabilizes the plasma
membrane but not the nuclear membrane; SLO and Lysolecithin
(LL) together permeabilize the plasma membrane and nuclear
membrane [15]. Permeabilization was tested using different sizes
of dextran (Figure S3a). We then compared transcription from
transplanted nuclei, comparing those treated with SLO alone and
Author Summary
Cells are dividing very actively at a time in development
when new gene expression and new cell lineages arise. At
mitosis, most transcription factors are temporarily dis-
placed from chromosomes. We show that, after transplan-
tation to oocytes, somatic cell nuclei that have been
synchronized in mitosis can be reprogrammed to pluripo-
tency gene expression up to 100 times faster than
interphase nuclei. We find that, as cells traverse mitosis,
their genes pass through a temporary phase of unusually
high responsiveness to oocyte reprogramming factors
(mitotic advantage). Many other genes in the genome
have also shown a mitotic advantage, which affects the
rate rather than the final level of transcriptional enhance-
ment. This is attributable to a chromatin state rather than
to more rapid passage of reprogramming factors through
the nuclear membrane. Histone H2A deubiquitination at
mitosis is required for the acquisition of mitotic advantage.
Our results support the general principle that a temporary
access of cytoplasmic factors to genes during mitosis
facilitates somatic cell nuclear reprogramming and the
acquisition of new cell fates in normal development.
Mitotic Advantage
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Figure 1. Mitotic nuclei are reprogrammed much more efficiently than interphase nuclei. (a) Nuclear transplantation procedure used in
this and the following experiments. (b) DNA content analysis of donor cells used for nuclear transplantation to oocytes confirms enrichment of
specific cell cycles stages. (c) Donor nuclei in the later stages of the cell cycle reprogram better than those from earlier stages. Nuclei from C2C12 cells
arrested at each stage of the cell cycle or growing in the absence of inhibitor were used as donor material for NT to oocyte GVs. The figure shows the
relative expression for each of the indicated genes at 38 h after transplantation compared to unarrested donor cells (n=3). Supporting data can be
found in Data S1.
doi:10.1371/journal.pbio.1001914.g001
Mitotic Advantage
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those treated with SLO and LL. The transcription ratio following
these two procedures shows no advantage when the nuclear
envelope is permeabilized (Figure S3b).
We conclude that the presence of an intact interphase nuclear
envelope does not explain the mitotic advantage.
The Mitotic Advantage Is Due to Chromatin Composition
Because the difference in reprogramming rate between
interphase and mitotic donor cells is maintained after extensive
permeabilization of the interphase nuclear membrane, we asked
if the source of the difference lies in the chromatin of the two
donor cell preparations. To answer this, we mildly sonicated
both interphase and mitotic donor cell preparations to give
fragments of chromatin of similar sizes (Figure 4a and b),
injected these preparations in parallel with a permeabilized cell
preparation into oocyte GVs, and assessed gene reactivation by
RT-qPCR (Figure 4c). It is clear that the difference in the rate
of gene reactivation from interphase and mitotic nuclei is
maintained when the injected material is sonicated chromatin as
opposed to whole nuclei. This suggests that the ‘‘mitotic
advantage’’ is present in the chromatin of mitotic cells. This
result also confirms that the difference between interphase and
mitotic donor cells is not due to the interphase nuclear
membrane, nor to any other aspect of nuclear organization
that is eliminated by sonication.
The difference between interphase and mitotic reprogramming
is, however, abolished when genomic DNA prepared from donor
nuclei is injected into oocyte GVs (Figure 4d); this excludes
differences at the DNA level (sequence and DNA methylation for
example) as possible sources of the difference in reprogramming
between interphase and mitotic samples. The possibility of DNA
methylation accounting for the mitotic effect was further excluded
by bisulphite analysis of specific loci on mitotic and interphase
DNAs, as this revealed no mitosis-specific differences (Figure 4e).
These two results indicate that whatever accounts for the
difference between mitotic and interphase donor cells is not
present at the level of genomic DNA itself but is in non-DNA
components of chromatin.
Figure 2. Mitotic advantage is due to an increased rate of reprogramming. (a) Live imaging of mixed mitotic and interphase nuclei injected
into the GVs of oocytes expressing fluorescently labelled histone B4 or histone H2B. Mitotic chromatin becomes decorated with oocyte-derived
factors to a far greater degree than interphase nuclei 2 h after nuclear transplantation. The arrows indicate interphase (I) or mitotic (M) nuclei. (b)
Mitotic donor nuclei (M) display actively transcribing RNA Pol II far more rapidly than interphase nuclei (I) when these nuclei are co-injected into
oocyte GVs. Immunofluorescent staining against a mixture of interphase and mitotic donor nuclei injected into the oocyte GV and fixed at 3 min or
between 1 and 2 h after transplantation using antibodies against active poI II (magenta). (c) A time course of expression by mitotic and interphase
donor nuclei shows that the difference between these nuclei decreases with time, suggesting that the eventual amount of reprogramming is similar
in the two nuclear types but that initiation of transcription is much more rapid in mitotic nuclei. Supporting data can be found in Data S1.
doi:10.1371/journal.pbio.1001914.g002
Mitotic Advantage
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Figure 3. Mitotic advantage is independent of nuclear membrane permeability. (a) Design of permeability assay. (b) Under normal
conditions of plasma membrane permeabilization by digitonin with no nuclear permeabilization, mitotic chromatin (M arrows) takes up histones B4
and H2B faster than interphase nuclei (I arrows). (c) When double permeabilized by Digitonin and Triton X, interphase nuclei and mitotic chromatin
take up these histones at a similar rate. (d) After double permeabilization, the mitotic advantage of mitotic nuclei is still very large, as judged by RT-
qPCR. Supporting data can be found in Data S1.
doi:10.1371/journal.pbio.1001914.g003
Mitotic Advantage
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Mitotic Advantage Is Independent of Most Salt-Released
Chromatin Factors
As the mitotic advantage is likely to be due either to the loss
or gain of chromatin binding factors, we removed most of these
from our donor suspension of interphase nuclei by incubating
such nuclei in a high-salt Triton buffer. We thereby tested
whether a loss of chromatin binding factors at mitotic entry
could remove the mitotic advantage. We also largely depleted
chromatin binding factors from permeabilized mitotic cells and
thus removed many chromatin factors that may be gained by
cells entering mitosis. The depletion of chromatin binding
factors was achieved with 300 mM salt and Triton, which
removed most nonhistone DNA binding factors. A scheme of
the cell preparation and examples of the proteins removed are
shown in Figure 5a and 5c. It can be seen that the great
majority of the nonhistone chromosomal proteins that have
been tested and that normally exist in interphase nuclei have
been removed from mitotic chromatin by 300 mM salt and
Triton. Nevertheless interphase nuclei depleted of salt soluble
nuclear protein (300 mM sample) do not acquire the same
reprogramming responsiveness as mitotic donor material
(Figure 5b). Likewise, extensive protein removal from mitotic
donor material (Figure 5c) before nuclear transplantation does
not abolish the mitotic advantage (mitotic 300 mM; Figure 5b),
indicating that the acquisition of chromosomal proteins by
mitotic nuclei does not account for this advantage.
Independently of salt release experiments, we tested topo-
isomerase II whose activity increases from S phase to the end of
G2. The inhibition of topoisomerase II and of its adaptor
molecules 14-3-3z and H3S10ph by inhibitors, inhibitory
peptides, and antibody injection in transplanted mitotic nuclei
did not reduce the mitotic advantage. We also found that salt
release removes topoisomerase from mitotic chromatin, as in
experiments shown in Figure 5c, but does not change the
mitotic advantage.
We conclude that a loss of salt-soluble chromatin binding factors
does not account for the mitotic advantage. It is likely therefore
that the source(s) of the difference is either a non-salt-soluble factor
(gained or lost at mitotic entry), a covalent modification of
chromatin, or the spatial arrangement of nucleosomes.
Histone Acetylation, Phosphorylation, and Methylation
We next considered covalent histone modifications that may be
lost or gained on mitotic chromatin compared to interphase
chromatin. A large number of histone modifications are associated
with mitotic entry [16,17], as well as changes in nucleosome
positioning and in chromatin compaction. We first tested the most
striking changes involving global histone deacetylation, phosphor-
ylation, and some small increases in histone H3 lysine 4 and 9
methylation that have been seen on mitotic chromatin [16,18,19].
Histone deacetylation in mitotic cells is successfully inhibited
during mitotic synchronization by the histone deacetylase inhibitor
TSA (Figure 6a). Histone phosphorylation in mitotic cells is
inhibited by the Aurora B/JAK inhibitor AT9823 (Figure 6b).
Nevertheless, the mitotic advantage persists after both of these
treatments (Figure 6c and 6d). Similarly, the removal of mitotic
histone phosphorylation from the Sox2 gene by protein phospha-
tase treatment of mitotic and interphase donor cells before nuclear
transplantation also failed to abrogate the mitotic effect (Figure
S4a and b). A small (2-fold) local increase in Sox2 locus histone
methylation at mitosis (Figure S4c and d), seen by ChIP in mitotic
chromatin, is eliminated by the methylation of MTA (not shown),
but the mitotic advantage is retained (Figure 6e).
Histone Ubiquitination
In normal cells, histone ubiquitination (primarily H2AK119Ub
and H2BK120Ub) is dramatically reduced at mitotic entry [16].
H2AK119Ub is associated with transcriptional repression [20].
Thus, a reduction in H2A ubiquitination at mitosis is an attractive
candidate to explain the enhanced reprogramming of mitotic
chromatin. We first tested the effect of increasing ubiquitination of
mitotic chromatin, by preparing nuclei for injection in the
presence of iodoacetimide (IAA), which inhibits deubiquitinases
(Figure 7a) [21]. Under normal conditions, interphase chromatin
is at least five times more globally ubiquitinated than mitotic
chromatin (Figure 7a,b). The inhibition of mitotic deubiquitina-
tion by IAA increases the ubiquitin level in mitotic chromatin, so
that it is nearly equal to that of interphase nuclei (Figure 7c).
When tested for transcription in oocytes, hyperubiquitinated
mitotic chromatin by IAA does not show an advantage over
interphase chromatin (Figure 7d), in accord with the idea that the
deubiquitinated state of normal mitotic chromatin could account
for its special transcriptional advantage.
As further support for this idea, we tried to remove ubiquitin
from interphase nuclei with a recombinant deubiquitinase (Ubp-
M), and then tested the effect of this by oocyte injection followed
by RT-qPCR. Treatment of interphase nuclei with Ubp-M
removes histone ubiquitination (Figure 7g). However, unexpect-
edly, we see that the removal of histone ubiquitination by Ubp-M
does not significantly enhance the reprogramming of interphase
nuclei, so that they behave the same, in this respect, as mitotic
chromatin (Figure 7h). This suggested that deubiquitination itself
is not sufficient to confer mitotic advantage. We hypothesized that
H2A deubiquitination is a required step in a series of chromatin
remodelling events that eventually lead to mitotic advantage. We
therefore chose to reduce the ubiquitinated state of interphase
nuclei in living cells in order to allow events downstream of
ubiquitin-depleted chromatin to take place. The inhibitor MG-132
is thought to lower histone ubiquitination by reducing the pool of
free ubiquitin through inhibition of the proteasome. MG-132
treatment of interphase nuclei before injection to oocytes
(Figure 7a) gave a partial but significant reduction in H2A
ubiquitination on Sox2 (Figure 7e compared to 7b); it also
resulted in a substantial enhancement of oocyte-induced tran-
scription from interphase, but not mitotic chromatin (Figure 7f).
The increase in ubiquitination of transplanted mitotic nuclei,
coupled with the removal of the mitotic advantage, shows that
chromatin ubiquitination contributes to the mitotic advantage. It
may, however, not be sufficient to explain the whole phenomenon,
because we do not achieve a complete mitotic advantage in
interphase nuclei by deubiquitination.
Discussion
Our results show a substantial effect of the cell cycle stage of
donor nuclei in nuclear transfer experiments. The reason why this
has not been seen before in some of the older nuclear transfer
experiments with eggs is probably for several reasons. One is that
the somatic nuclei used as donors were not able to be well
synchronized [22–24]. Another is that tests have involved the
normality of development, rather than gene activity. Third, and
most importantly, tests have been carried out on cell dividing eggs,
whereas our work has tested gene transcription in the complete
absence of DNA replication or cell division. The more recent
results of [6] are in agreement with the work described here. The
success of the first mammal cloning work was attributed in part to
the use of donor cells in G0 [25,26]; this result was not, however,
found by others [27–30]. Lemaitre et al. [6] have described a
Mitotic Advantage
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dramatic effect of mitosis on the efficiency of DNA replication by
egg cytoplasm, but transcription could not be tested in their
extract experiments. Egli et al. [3] have proposed an important
role for mitosis in permitting chromosomal protein exchange in
mouse nuclear transfer experiments but not necessarily on gene
transcription. Our results are therefore in accord with previous
work, but reveal a specific effect of mitosis on gene transcription.
An important component responsible for the acquisition of
mitotic advantage appears to be the removal of ubiquitin from
histone H2A or H2B in mitotic chromatin. Ubiquitination of
Figure 4. Sonication does not eliminate mitotic advantage. (a) Interphase and mitotic donor nuclei were mildly sonicated to fragment the
chromatin as shown by DAPI staining of the four kinds of donor nuclei. (b) The major proportion of DNA in both sonicated samples is above the size
exclusion limit of the gel, confirming mild sonication. (c) Interphase and mitotic nuclei or corresponding sonicated chromatin preparations were
transplanted into oocyte GVs and gene reactivation analyzed by RT-qPCR after 42 h. The mitotic advantage is retained on fragments of chromatin.
Supporting data can be found in Data S1. (d) Genomic DNA prepared from interphase and mitotic cells was injected into oocyte GVs and gene
transcription assessed by RT-qPCR. There is no significant difference between interphase and mitotic DNA with respect to gene activation in the
oocyte at either of the indicated time points. Supporting data can be found in Data S1. (e) There is no observable difference in DNA methylation
between interphase and mitotic cells as determined by pyrosequencing of bisulphite-converted genomic DNA (horizontal lines represent the
indicated DNA sequences, with balls representing individual CpG dinucleotides; black filling represents the percentage of methylation for each site).
Solid black bars represent the positions of known transcription factor binding sites, such as SP1/HRE. OS is Oct-Sox, PD is Pou-Domain, and SRR is the
Sox2 Regulatory Region, and genomic distances are presented below each map, set relative to the transcriptional start site of each gene.
doi:10.1371/journal.pbio.1001914.g004
Mitotic Advantage
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Figure 5. Removal of salt-soluble factors from interphase C2C12 nuclei. (a) Design of salt depletion procedure. (b) 300 mM salt does not
remove the mitotic advantage of mitotic nuclei, nor does it make interphase nuclei behave like mitotic chromatin by loss of DNA-binding factors.
Salt-treated samples were injected to oocytes and cultured for 40 h and then analyzed by RT-qPCR. Supporting data can be found in Data S1. (c) Two
independent experiments show that the majority of chromatin binding factors can be depleted from nuclei by 300 mM salt and Triton when
compared to 75 mM salt, which should not remove chromatin-bound factors. The blemish for topoisomerase II (75 mM,M) is not in the position of
this protein.
doi:10.1371/journal.pbio.1001914.g005
Mitotic Advantage
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histones is primarily monoubiquitination, and we assume that this
is the modification involved in mitotic advantage. H2A ubiquiti-
nation on lysine 119 is associated with transcriptional repression,
particularly of lineage-specifying genes in ES cells [31], possibly
through its association with members of the polycomb repressive
proteins [32]. It could be envisaged that the deubiquitination of
chromatin seen at mitotic entry permits this mitotic advantage by
removing this inhibitory mark or the associated binding proteins
Figure 6. Most mitotic histone modifications do not distinguish mitotic chromatin from interphase nuclei. (a) Western blot showing
TSA inhibition of the normal mitotic deacetylation of histone H3K9ac. (b) Western blot showing that AT2983 prevents the normal mitotic
phosphorylation of histone H3. (c) Mitotic nuclei prepared in the presence of TSA maintain the mitotic advantage. Supporting data can be found in
Data S1. (d) Inhibiting normal mitotic phosphorylation by AT2983 has no adverse effect on mitotic advantage. Supporting data can be found in Data
S1. (e) MTA inhibits mitotic methylation of H3K4me3 and H3K9me3, both of which are normally increased at the Sox2 locus in C2C12 cells. This does
not change the mitotic advantage. Supporting data can be found in Data S1.
doi:10.1371/journal.pbio.1001914.g006
Mitotic Advantage
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Figure 7. Histone ubiquitination can explain the mitotic advantage. (a) Western blot for histone H2AK119Ub and H2B120Ub from interphase
and mitotic donor cells treated with IAA or MG132. (b) ChIP analysis for ubiquitinated histone H2A shows a large difference between mitotic
chromatin and interphase nuclei for several genomic regions. (c) IAA largely removes the deubiquitinated state of mitotic chromatin in several gene
regions. None of these values are significantly different from one another. Supporting data can be found in Data S1. (d) Mitotic advantage is
eliminated by IAA treatment. Supporting data can be found in Data S1. (e) H2AK119 ubiquitination in interphase nuclei is reduced by MG132.
Supporting data can be found in Data S1. (f) RT-qPCR of interphase and mitotic nuclei treated with MG132 after nuclear transfer to oocytes;
interphase transcription is much enhanced. Supporting data can be found in Data S1. (g) Western blot to show in vitro deubiquitination of interphase
and mitotic donor nuclei. (h) RT-qPCR transcription analysis of Ubp-M-treated donor nuclei 36 h after nuclear transfer. Supporting data can be found
in Data S1.
doi:10.1371/journal.pbio.1001914.g007
Mitotic Advantage
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[33]. In keeping with this idea, we have been able to partly
simulate the mitotic effect by biochemically removing histone
ubiquitination in interphase donor cells.
What could be the significance of the mitotic advantage
identified here? In our experiments, the mitotic advantage takes
place during the early stages of transcriptional activation, and is no
longer seen after 2 d. In normal dividing cells, mitosis lasts for only
a few hours. We therefore think that mitosis is a time when cells
can most easily change their chromatin state, exchange transcrip-
tion factors, and embark on a new lineage. When a cell has
adopted a new fate, its daughter cells will usually follow the same
lineage, unless an exchange of nuclear components takes place.
The acceleration of postmitotic transcriptional activation [34] may
be an associated phenomenon.
Materials and Methods
Cell Culture
Cells were cultured in DMEM (D5796, Sigma; E15-810, PAA;
41965-062, Invitrogen) with 10% FCS (10270106, Invitrogen),
100 units/ml Penicillin-Streptomycin (15140-122, Invitrogen), and
0.25 mg/ml Fungizone (15240-096, Invitrogen). Inhibitors used for
various experiments include the following: 59-Deoxy-59-
(methylthio)adenosine (MTA)(D5011, Sigma) used at 1 mg/ml,
Aphidicolin (A0781, Sigma) at 1 mg/ml, AT9823 (gift from M.
Dawson) used at 100 nM; ICRF-90 (I4659, Sigma) at 1 mg/ml,
iodoacetamide (IAA) made freshly and used at 10 mM, MG-132
(Sigma) used at 4 mM, Nocodazole (M1404, Sigma) at 75–
100 nM; Taxol (T7402, Sigma) at 1 mM, Thymidine (T1895,
Sigma), and Trichostatin A (T8552, Sigma) at 1 mg/ml.
Synchronization
Cell synchronization was achieved according to the scheme in
Figure S1A. In general, media containing the desired inhibitor
were applied to unsynchronized cells a day after seeding for 16–
20 h. For mitotic cells, seeded cells were initially arrested in 2 mM
thymidine for 16–24 h, washed 36 in PBS, released into fresh
media for 6–12 h, and then media replaced with Nocodazole or
Taxol containing media for 10–16 h, after which rounded cells
were detached by ‘‘shake-off’’ and the culture media harvested for
the mitotic cell fraction. G1 arrest was achieved by Serum
starvation for 72 h.
Nuclear and Karyoplast Preparation and Transplantation
to Oocyte GVs
Cells in suspension (either from mitotic shake-off or
trypsinization of adherent cells) were washed twice in PBS,
transferred to SuNaSP, and permeabilized with Digitonin (40–
100 mg/ml) for 3 min on ice. The reaction was stopped by
addition of and excess of SuNaSP-BSA and the nuclei
concentrated to an appropriate volume for GV transfer [12].
Nuclear transplantation to oocyte GVs was performed as
described in [12].
Media for Permeabilization (Nuclear Suspension Media)
The following media were used for permeabilization: SuNaSP,
0.25 M Sucrose, 75 mM NaCl, 0.5 mM Spermidine, 0.15 mM
Spermine; SuNaSP-BSA, SuNaSP with 3% (w/v) BSA; and
HPRicLS, Final [16] Hepes 20 mM, KCl 75 mM, MgCl2 1.5 mM.
Salt Depletion of Donor Cells
Cells were permeabilized with Digitonin and incubated for
15 min in prebuffer (20 mM Hepes, 75 mM KCl, 1.5 mM
MgCl2, 25 mg/ml Gelatin, 60 mg/ml BSA) and washed twice
into permeabilization buffer (20 mM Hepes, 75 or 300 mM KCl,
1.5 mM MgCl2, 0.2% TritonX100, 12 mg/ml Gelatin, 30 mg/ml
BSA). Cells were then extensively washed (20 mM Hepes, 75 mM
KCl, 1.5 mM MgCl2) and resuspended in a suitable volume of
SuNaSP-BSA for nuclear transplantation.
In Vitro Deubiquitination and Dephosphorylation of
Donor Cells
Cells were permeabilized in Digitonin, incubated in ‘‘prebuffer,’’
washed into permeabilization buffer (75 mM salt), washed in
SuNaSP, and then transferred into a suitable reaction buffer with
or without recombinant enzyme. Dephosphorylation was performed
with Protein Phosphatase I (NEB, P0754S) in HPRicLS (20 mM
Hepes, 75 mM KCl, 1.5 mM MgCl2) and Deubiquitination
performed using recombinant enzyme prepared from insect cells (as
described in [33]) in buffer (50 mM NaCl, 50 mM Tri-Cl PH 8.0,
1 mM DTT, 16Complete EDTA-free Protease inhibitor [Roche]).
After enzyme treatment, cells were washed in HPRicLS and SuNaSP
and resuspended in a suitable volume of SuNaSP-BSA.
Flow Cytometry
PBS washed cell suspensions were (fixed in ethanol and stained
with 50 mg/ml propidium iodide). DNA content analyses were
then performed on a FACSCalibur cytometer (BD Bioscience).
Antibodies for ChIP and Western Blot
The following antibodies were used: aAurura B (AIM1) (Cell
Signalling, 3094), aBmi1 (Cell Signalling, 6964), aBRD4 (Cell
Signalling, 12183), aCTCF (Cell Signalling, 3418), aCyclinB (Cell
Signalling, 4138), aDNMT1 (Abcam, ab92453), aH2AK119Ub
(Cell Signalling, 8240), aH2BK120Ub (Cell Signalling, 5546),
aH3 (Abcam, ab1791 and Cell Signalling, 4620), aH3K4me3
(Abcam, ab8580), aH3K9ac (Cell Signalling, 9649), aH3K9me2/
3 (Cell Signalling, 5327), aH3S10ph (Sigma, H 0412), aH4
(Abcam, ab31830), aHP1a (Cell Signaling, 2616), aphosphoSer2-
PolII (Covance, MMS-129R), aRunx2 (Cell Signalling, 8486), and
aTBP (Abcam, ab62125).
RT-qPCR
RT-qPCR was performed as described in [11]. Unless otherwise
stated, results are normalized to VegT (correcting for intrasample
RNA extraction variation) and G3PDH (correcting for nuclear
number differences between injected oocyte samples). Error bars
indicate SME or standard deviation, and significance is determined
by unpaired Student t test, with p,0.05 being considered significant.
All experiments presented were single experiments representative of
at least three experimental repeats unless otherwise noted.
Bisulphite and Pyro Sequencing
Genomic DNA was prepared using DNeasy blood and tissue
kits (69504, Qiagen), bisulphite conversion was performed
using EpiTect Bisulfite Kit (59104, Qiagen), and primer
sequences for DNA preparation were designed using Qiagen.
Pyrosequencing was performed on a Qiagen Pyromark Q96 ID
using PyroMark Gold Q96 Reagents (972804, Qiagen) and
PyroMark PCR Kit (978705, Qiagen), as per the manufactur-
er’s recommendations.
Supporting Information
Data S1 Supporting histogram data.
(XLSX)
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Figure S1 (a) Design of cell cycle synchronization procedure. (b)
10T1/2 cells show a mitotic advantage by transcription assay after
injection into oocytes. Supporting data can be found in Data S1.
(c) Shake-off procedure to enrich for mitotic cells without
inhibitors also displays some mitotic advantage when compared
to interphase cells. The proportion of cells in mitosis for these
samples is indicated in the adjacent table. Supporting data can be
found in Data S1. (d) Taxol-synchronized cells give the same
transcriptional enrichment as nocodazole-arrested cells after
transplantation to oocyte GVs. Supporting data can be found in
Data S1. (e) G1/G0-arrested cells, treated with Nocodazole, show
no enhancement of pluripotency gene transcription after nuclear
transplantation to oocyte GVs. Supporting data can be found in
Data S1.
(TIF)
Figure S2 Design of experiments for nuclear incorporation
assays. (a) A mixture of mitotic and interphase donor nuclei are
injected into oocyte GVs, 24 h after the oocytes have been injected
with RNAs encoding fluorescently labelled (GFP or Cherry)
proteins. The resulting GVs are then isolated from the oocyte and
the transplanted nuclei examined by confocal microscopy. I,
interphase; M, mitotic. (b) The oocyte-specific transcription factor
TBP2 (red) is taken up by mitotic nuclei to a far greater extent
than interphase nuclei by 48 h. GFP labelled histone B4 is used to
mark the position of transplanted mitotic and interphase nuclei.
The arrows indicate examples of one interphase (yellow) and one
mitotic nucleus (white).
(TIF)
Figure S3 Permeabilization of the nuclear membrane does not
reduce mitotic advantage. (a) 3 KDa dextran enters SLO-
permeabilized nuclei, but 70 KDa dextran does not (black
spheres). SLO and LL together permit entry of 70 KDa dextran
nucleoplasm. The table illustrates the proportion of permeabilized
plasma and nuclear membranes by these treatments. (b)
Transcriptional reprogramming 24 h after transplantation of
SLO or SLO+LL permeabilized nuclei to oocyte GVs is similar.
Supporting data can be found in Data S1.
(TIF)
Figure S4 Phosphatase treatment does not decrease mitotic
advantage. (a) Phosphatase removes phosphorylation of H3S10
from mitotic nuclei. (b) Phosphatase treatment does not eliminate
mitotic advantage. Supporting data can be found in Data S1. (c)
MTA may be used to reduce the local methylation of some genes
on mitotic entry. ChIP against the Sox2 promoter and coding
sequence using an antibody against H2K4me3 and (d) H3K9me2/
3. Supporting data can be found in Data S1.
(TIF)
Table S1 List of genes that are up-regulated in mitotic nuclei
transplanted to Xenopus oocytes when compared to interphase
nuclei transplanted to Xenopus oocytes. We have identified by
RNA-seq genes that are consistently expressed 48 h after nuclear
transfer of interphase transformed mouse embryonic fibroblasts to
Xenopus oocytes (manuscript under consideration). We used this
set of 4,210 genes expressed after nuclear transfer in a comparison
with one experiment in which mitotic nuclei transcription
following nuclear transfer was also measured by RNA-seq. This
led to the identification of 617 genes up-regulated from mitotic
nuclei compared to interphase nuclei. The table shows the name of
these genes, RPKM from transplanted interphase nuclei (mean of
three independent experiment), RPKM from transplanted mitotic
nuclei (one experiment), as well as the ratio of mitotic to interphase
RPKMs.
(XLSM)
Acknowledgments
The authors thank the following people for reagents and/or advice:
Andrew Bannister, Mark Dawson, Ron Laskey, Jon Pines, Kei Miyamoto,
Eva Ho¨rmanseder, Magda Koziol, Marta Teperek, Hengin Wang, and
George Allen.
Author Contributions
The author(s) have made the following declarations about their
contributions: Conceived and designed the experiments: RPH-S JJ VP
JBG. Performed the experiments: RPH-S JJ VP JBG. Analyzed the data:
RPH-S JJ VP JBG. Contributed reagents/materials/analysis tools: RPH-S
JJ VP JBG. Contributed to the writing of the manuscript: RPH-S JJ VP
JBG.
References
1. Holtzer H, Rubinstein N, Fellini S, Yeoh G, Chi J, et al. (1975) Lineages,
quantal cell cycles, and the generation of cell diversity. Q Rev Biophys 8: 523–
557.
2. Martı´nez-Balba´s MA, Dey A, Rabindran SK, Ozato K, Wu C (1995)
Displacement of sequence-specific transcription factors from mitotic chromatin.
Cell 83: 29–38.
3. Egli D, Birkhoff G, Eggan K (2008) Mediators of reprogramming: transcription
factors and transitions through mitosis. Nat Rev Mol Cell Biol 9: 505–516.
4. Egli D, Rosains J, Birkhoff G, Eggan K (2007) Developmental reprogramming after
chromosome transfer into mitotic mouse zygotes. Nature 447(7145): 679–685.
5. Egli D, Eggan K (2010) Recipient cell nuclear factors are required for
reprogramming by nuclear transfer. Development 137(12): 1953–1963.
6. Lemaitre J-M, Danis E, Pasero P, Vassetzky Y, Mechali M (2005) Mitotic
remodeling of the replicon and chromosome structure. Cell 123: 787–801.
7. Ganier O, Bocquet S, Peiffer I, Brochard V, Arnaud P (2011) Synergic
reprogramming of mammalian cells by combined exposure to mitotic Xenopus
egg extracts and transcription factors. Proc Natl Acad Sci USA 108: 17221–
17336.
8. Tsubouchi T, Soza-Ried J, Brown K, Piccolo FM, Cantone I, et al. (2013) DNA
synthesis is required for reprogramming mediated by stem cell fusion. Cell 152:
873–883.
9. Foshay KM, Looney TJ, Chari S, Mao FF, Lee JH, et al. (2012) Embryonic stem
cells induce pluripotency in somatic cell fusion through biphasic reprogramming.
Mol Cell 46: 159–170.
10. Chiu CP, Blau HM (1984) Reprogramming cell differentiation in the absence of
DNA synthesis. Cell 37: 879–887.
11. Vierbuchen T, Wernig M (2011) Direct lineage conversions: unnatural but
useful? Nat Biotechnol 29: 892–907.
12. Halley-Stott RP, Pasque V, Astrand C, Miyamoto K, Simeoni I, et al.
(2010) Mammalian nuclear transplantation to germinal vesicle stage Xenopus
oocytes—a method for quantitative transcriptional reprogramming. Methods 51:
56–65.
13. Driessens G, Blanpain C (2011) Long live Sox2:Sox2 lasts a lifetime. Cell Stem
Cell 9: 283–284.
14. Jullien J, Astrand C, Halley-Stott RP, Garrett N, Gurdon JB (2010)
Characterization of somatic cell nuclear reprogramming by oocytes in which
a linker histone is required for pluripotency gene reactivation. Proc Natl Acad
Sci USA 107: 5483–5488.
15. Coverley D, Downes CS, Romanowski P, Laskey RA (1993) Reversible effects of
nuclear membrane permeabilization on DNA replication: evidence for a positive
licensing factor. J Cell Biol 122: 985–992.
16. Wang F, Higgins JMG (2013) Histone modifications and mitosis: countermarks,
landmarks, and bookmarks. Trends Cell Biol 23: 175–184.
17. Xu D, Bai J, Duan Q, Costa M, Dai W (2009) Covalent modifications of
histones during mitosis and meiosis. Cell Cycle 8: 3688–3694.
18. Valls E, Sa´nchez-Molina S, Martı´nez-Balba´s MA (2005) Role of histone
modifications in marking and activating genes through mitosis. J Biol Chem 280:
42592–42600.
19. Terrenoire E, McRonald F, Halsall JA, Page P, Illingworth RS, et al. (2010)
Immunostaining of modified histones defines high-level features of the human
metaphase epigenome. Genome Biol 11: R110.
20. Bannister AJ, Kouzarides T (2011) Regulation of chromatin by histone
modifications. Cell Res 21: 381–395.
21. Ke Q, Ellen TP, Costa M (2008) Nickel compounds induce histone
ubiquitination by inhibiting histone deubiquitinating enzyme activity. Toxicol
Appl Pharmacol 228: 190–199.
Mitotic Advantage
PLOS Biology | www.plosbiology.org 12 July 2014 | Volume 12 | Issue 7 | e1001914
22. McAvoy JW, Dixon KE, Marshall JA (1975) Effects of differences in mitotic
activity, stage of cell cycle, and degree of specialization of donor cells on nuclear
transplantation in Xenopus laevis. Dev Biol 45: 330–339.
23. Ellinger MS (1978) The cell cycle and transplantation of blastula nuclei in
Bombina orientalis. Dev Biol 65: 81–89.
24. Beroldingen von CH (1981) The developmental potential of synchronized
amphibian cell nuclei. Dev Biol 81: 115–126.
25. Campbell KH, Loi P, Otaegui PJ, Wilmut I (1996) Cell cycle co-ordination in
embryo cloning by nuclear transfer. Rev Reprod 1: 40–46.
26. Campbell KH, McWhir J, Ritchie WA, Wilmut I (1996) Sheep cloned by
nuclear transfer from a cultured cell line. Nature 380: 64–66.
27. Wakayama T, Rodriguez I, Perry AC, Yanagimachi R, Mombaerts P (1999)
Mice cloned from embryonic stem cells. Proc Nat Acad Sci USA 96: 14984–
14989.
28. Cibelli JB, Stice SL, Golueke PJ, Kane JJ, Jerry J, et al. (1998) Cloned transgenic
calves produced from nonquiescent fetal fibroblasts. Science 280: 1256–1258.
29. Yabuuchi A, Yasuda YU, Kato Y, Tsunoda Y (2004) Effects of nuclear transfer
procedures on ES cell cloning efficiency in the mouse. J Reprod Dev 50: 263–
268.
30. Oback B, Wells DN (2007) Donor cell differentiation, reprogramming, and
cloning efficiency: elusive or illusive correlation? Mol Reprod Dev 74: 646–654.
31. Endoh M, Endo TA, Endoh T, Isono K, Sharif J, et al. (2012) Histone H2A
mono-ubiquitination is a crucial step to mediate PRC1-dependent repression of
developmental genes to maintain ES cell identity. PLoS Genet 8(7): e1002774.
32. Wang H, Wang L, Erdjument-Bromage H, Vidal M, Tempst P, et al. (2004)
Role of histone H2A ubiquitination in Polycomb silencing. Nature 431: 873–
878.
33. Joo H-Y, Zhai L, Yang C, Nie S, Erdjument-Bromage H, et al. (2007)
Regulation of cell cycle progression and gene expression by H2A deubiquitina-
tion. Nature 449: 1068–1072.
34. Zhao R, Nakamura T, Fu Y, Lazar Z, Spector DL (2011) Gene bookmarking
accelerates the kinetics of post-mitotic transcriptional reactivation. Nat Cell Biol
13: 1296–1304.
Mitotic Advantage
PLOS Biology | www.plosbiology.org 13 July 2014 | Volume 12 | Issue 7 | e1001914
